Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.

Treviño LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV.

J Clin Oncol. 2009 Dec 10;27(35):5972-8. doi: 10.1200/JCO.2008.20.4156. Epub 2009 Nov 9.

2.

Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.

Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Möricke A, Stanulla M, Schrappe M, Langer T.

Blood. 2013 Jun 27;121(26):5145-53. doi: 10.1182/blood-2013-01-480335. Epub 2013 May 7.

3.

Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.

Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Piñan MA, Garcia-Miguel P, Navajas A, Garcia-Orad A.

Pediatr Blood Cancer. 2011 Oct;57(4):612-9. doi: 10.1002/pbc.23074. Epub 2011 Mar 8.

PMID:
21387541
4.

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.

Ramsey LB, Bruun GH, Yang W, Treviño LR, Vattathil S, Scheet P, Cheng C, Rosner GL, Giacomini KM, Fan Y, Sparreboom A, Mikkelsen TS, Corydon TJ, Pui CH, Evans WE, Relling MV.

Genome Res. 2012 Jan;22(1):1-8. doi: 10.1101/gr.129668.111. Epub 2011 Dec 6.

5.

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.

Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds SB, Neale G, Treviño LR, French D, Campana D, Downing JR, Evans WE, Pui CH, Devidas M, Bowman WP, Camitta BM, Willman CL, Davies SM, Borowitz MJ, Carroll WL, Hunger SP, Relling MV.

JAMA. 2009 Jan 28;301(4):393-403. doi: 10.1001/jama.2009.7.

6.

Genome-wide study of methotrexate clearance replicates SLCO1B1.

Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, Martin PL, Cheng C, Devidas M, Pui CH, Evans WE, Hunger SP, Loh M, Relling MV.

Blood. 2013 Feb 7;121(6):898-904. doi: 10.1182/blood-2012-08-452839. Epub 2012 Dec 11.

7.

Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.

Csordas K, Lautner-Csorba O, Semsei AF, Harnos A, Hegyi M, Erdelyi DJ, Eipel OT, Szalai C, Kovacs GT.

Br J Haematol. 2014 Aug;166(3):410-20. doi: 10.1111/bjh.12886. Epub 2014 Apr 9.

PMID:
24712521
8.

Impact of SLCO1B1 521T > C variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.

Zhang HN, He XL, Wang C, Wang Y, Chen YJ, Li JX, Niu CH, Gao P.

Pediatr Blood Cancer. 2014 Dec;61(12):2203-7. doi: 10.1002/pbc.25191. Epub 2014 Aug 17.

PMID:
25130190
9.

[SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].

Zhang H, He X, Li J, Wang Y, Wang C, Chen Y, Niu C, Gao P.

Zhonghua Er Ke Za Zhi. 2014 Oct;52(10):770-6. Chinese.

PMID:
25537545
10.

Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.

Bhojwani D, Sabin ND, Pei D, Yang JJ, Khan RB, Panetta JC, Krull KR, Inaba H, Rubnitz JE, Metzger ML, Howard SC, Ribeiro RC, Cheng C, Reddick WE, Jeha S, Sandlund JT, Evans WE, Pui CH, Relling MV.

J Clin Oncol. 2014 Mar 20;32(9):949-59. doi: 10.1200/JCO.2013.53.0808. Epub 2014 Feb 18.

11.

High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.

Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T.

Clin Pharmacol Ther. 2006 Nov;80(5):468-76.

PMID:
17112803
12.

Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.

Lopez-Lopez E, Ballesteros J, Piñan MA, Sanchez de Toledo J, Garcia de Andoin N, Garcia-Miguel P, Navajas A, Garcia-Orad A.

Pharmacogenet Genomics. 2013 Feb;23(2):53-61. doi: 10.1097/FPC.0b013e32835c3b24.

PMID:
23222202
13.

Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.

Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolžan V, Jazbec J.

Eur J Clin Pharmacol. 2011 Oct;67(10):993-1006. doi: 10.1007/s00228-011-1046-z. Epub 2011 Apr 21.

PMID:
21509569
14.

Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma.

Goričar K, Kovač V, Jazbec J, Zakotnik B, Lamovec J, Dolžan V.

Pharmacogenet Genomics. 2014 Oct;24(10):514-21. doi: 10.1097/FPC.0000000000000083.

PMID:
25098908
15.

Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.

Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, Gilchrist GS, Bleyer WA.

Blood. 1998 Nov 15;92(10):3569-77.

16.

Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.

Csordas K, Hegyi M, Eipel OT, Muller J, Erdelyi DJ, Kovacs GT.

Anticancer Drugs. 2013 Feb;24(2):189-97. doi: 10.1097/CAD.0b013e32835b8662.

PMID:
23187460
17.

Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.

Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, Torii C, Yoshihara H, Tanigawara Y, Takahashi T, Kosaki K.

J Pediatr Hematol Oncol. 2006 Feb;28(2):64-8.

PMID:
16462575
18.

Germline genomic variants associated with childhood acute lymphoblastic leukemia.

Treviño LR, Yang W, French D, Hunger SP, Carroll WL, Devidas M, Willman C, Neale G, Downing J, Raimondi SC, Pui CH, Evans WE, Relling MV.

Nat Genet. 2009 Sep;41(9):1001-5. doi: 10.1038/ng.432. Epub 2009 Aug 16.

19.

SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.

Lima A, Bernardes M, Azevedo R, Monteiro J, Sousa H, Medeiros R, Seabra V.

Toxicol Sci. 2014 Nov;142(1):196-209. doi: 10.1093/toxsci/kfu162. Epub 2014 Aug 14.

20.

Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia.

Aumente D, Buelga DS, Lukas JC, Gomez P, Torres A, García MJ.

Clin Pharmacokinet. 2006;45(12):1227-38.

PMID:
17112298
Items per page

Supplemental Content

Write to the Help Desk